Document Detail

The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis.
MedLine Citation:
PMID:  16138225     Owner:  NLM     Status:  MEDLINE    
End-stage renal disease (ESRD) patients frequently develop structural cardiac abnormalities, particularly left ventricular hypertrophy (LVH). The mechanisms involved in these processes are not completely understood. In the present study, we evaluated a possible association between parathyroid hormone (PTH) levels and left ventricular mass (LVM) in patients with ESRD. Stable uremic patients on intermittent hemodialysis treatment were evaluated by standard two-dimensional echocardiography and their sera were analyzed for intact PTH. Forty-one patients (mean age 45 years, range 18 to 61 years), 61% males, who had been on hemodialysis for 3 to 186 months, were evaluated. Patients were stratified into 3 groups according to serum PTH: low levels (< 100 pg/ml; group I = 10 patients), intermediate levels (100 to 280 pg/ml; group II = 10 patients) and high levels (> 280 pg/ml; group III = 21 patients). A positive statistically significant association between LVM index and PTH was identified (r = 0.34; P = 0.03, Pearson's correlation coefficient) in the sample as a whole. In subgroup analyses, we did not observe significant associations in the low and intermediate PTH groups; nevertheless, PTH and LVM index were correlated in patients with high PTH levels (r = 0.62; P = 0.003). LVM index was also inversely associated with hemoglobin (r = -0.34; P = 0.03). In multivariate analysis, after adjustment for age, hemoglobin, body mass index, and blood pressure, the only independent predictor of LVM index was PTH level. Therefore, PTH is an independent predictor of LVH in patients undergoing chronic hemodialysis. Secondary hyperparathyroidism may contribute to the elevated cardiovascular morbidity associated with LVH in ESRD.
R B Randon; L E Rohde; L Comerlato; J P Ribeiro; R C Manfro
Related Documents :
696755 - Chronic hypervitaminosis a.
17130275 - Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization.
7244985 - Total parathyroidectomy and parathyroid autotransplantation in patients with chronic re...
6825315 - The need for a sufficient number of low level sera in comparisons of different serum vi...
19520215 - Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate ...
11840375 - Persistent elevation of c-reactive protein and ischemic heart disease in patients with ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-08-26
Journal Detail:
Title:  Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.]     Volume:  38     ISSN:  0100-879X     ISO Abbreviation:  Braz. J. Med. Biol. Res.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-09-02     Completed Date:  2006-04-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8112917     Medline TA:  Braz J Med Biol Res     Country:  Brazil    
Other Details:
Languages:  eng     Pagination:  1409-16     Citation Subset:  IM    
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hyperparathyroidism, Secondary / complications*
Hypertrophy, Left Ventricular / blood,  etiology*,  ultrasonography
Kidney Failure, Chronic / complications*,  therapy
Middle Aged
Multivariate Analysis
Parathyroid Hormone / blood*
Renal Dialysis*
Risk Factors
Reg. No./Substance:
0/Parathyroid Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A prospective study of hepatitis B virus markers in patients with chronic HBV infection from Brazili...
Next Document:  Umbilical cord blood and neonatal endothelin-1 levels in preterm newborns with and without respirato...